Radius Health United States

Radius is a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases.

Radius is committed to the research and development of new therapeutics for the large and underserved osteoporosis market. The Company's lead investigational drug product candidate, abaloparatide (BA058), is in development, in both injection (Abaloparatide-SC) and transdermal (Abaloparatide-TD) methods of administration, for the potential prevention of fractures in post-menopausal women at risk of fracture from osteoporosis.

Radius' clinical portfolio also includes a new investigational oral agent, RAD1901, a selective estrogen receptor down-regulator/degrader, or SERD, in development at higher doses for the potential treatment of breast cancer brain metastases, and at lower doses as a selective estrogen-receptor modulator, or SERM, for the potential treatment of vasomotor symptoms such as hot flashes.

Mr Robert Ward
CEO 

Ressler United States

Mrs Stephanie Ressler
Attorney 

Roche Innovation Center United States

Our location in the Alexandria Center for Life Science enables us to combine our expertise with that of world class researchers here in a vibrant scientific environment.

The Roche Translational and Clinical Research Center (TCRC) is part of the Pharma Research and Early Development (pRED) organization, and will serve as the hub for pRED activities in North America, underscoring the center’s importance to pRED and Roche. The TCRC staff is comprised of highly experienced drug developers who are focused on early clinical development of Roche drug candidates. In addition to advancing Roche’s existing portfolio, the TCRC experts will aim to access external innovation by identifying collaborations ranging from very early discovery platforms through advanced stage molecules.

Dr Fiona Mack, Ph.D.
Pharmaceutical Research and Early Development 

Roche Innovation Center New York United States

The Roche Translational and Clinical Research Center (TCRC) is part of the Pharma Research and Early Development (pRED) organization, and will serve as the hub for pRED activities in North America, underscoring the center’s importance to pRED and Roche. The TCRC staff is comprised of highly experienced drug developers who are focused on early clinical development of Roche drug candidates. In addition to advancing Roche’s existing portfolio, the TCRC experts will aim to access external innovation by identifying collaborations ranging from very early discovery platforms through advanced stage molecules.

Mr Robert A Silverman
Venture Lead, Roche Partnering 

Rockland Technimed Ltd United States

Rockland Technimed Limited is a diagnostic imaging company, committed to the early diagnosis and treatment of ischemic injury, through its patented Oxy-17® metabolic magnetic resonance imaging medium.

Rockland Technimed Limited (RTL) is a theranostic imaging company committed to the early diagnosis and treatment of hypoxic injury through Oxy-17®, its patented metabolic magnetic resonance imaging medium.  RTL has the world’s largest production source of Oxy-17® Gas, an enriched form of naturally available oxygen, in compliance with the cGMP requirement for medical gases, and commercially available in the United States and European Union for more than 20 years.  RTL’s lead preclinical candidate, Oxy-17® Fusion, is the first ready-to-use intravenous formulation of Oxy-17® Gas and is currently in regulatory marketing studies in Germany (European Union) and the United States.  Oxy-17® Fusion will be commercialized in the United States by RTL, and in the European Union with Nukem Isotopes GmbH. 
Mr Pradeep Gupte
Founder & CEO 

Rosellini Scientific United States

Ms Beth Rosellini
LP 

Rutgers Biomedical and Health Sciences (RBHS) - New Jersey Medical School United States

International Epidemiologist with wide ranging expertise in chronic and infectious diseases & interdisciplinary collaborations.

Private email:  stanweiss @ verizon.net


Stanley H. Weiss, MD has been on the RBHS (and legacy UMDNJ) faculties since 1987, and currently is Professor (with tenure) of Medicine at the New Jersey Medical School, and Professor of Epidemiology at the Rutgers School of Public Health. 

He graduated from Yale (1974, BA, summa cum laude and Phi Beta Kappa) and Harvard Medical School (1978, MD). He did a residency in Internal Medicine at Montefiore in the Bronx, and fellowships at the National Cancer Institute in Medical Oncology and in Epidemiology. Dr. Weiss is Board Certified in Internal Medicine and in Medical Oncology, and a fellow of the American College of Epidemiology (“FACE”) and the American College of Physicians (“FACP”).   

On November 2nd, 2015, he will be honored by the American Public Health Association with its Wade Hampton Frost Lecture, its top epidemiology research  award. 

His past professional awards include the NJ Public Health Association’s (NJPHA) highest award – the Dennis J. Sullivan Award (2012), the NJPHA Dr. Ezra Mundy Hunt Award (2007), the first recipient of the American Lung Association of NJ’s “CAREforAIRnj Award for Community  Outreach/Action/Advocacy, the “Cancer Liaison Physician Outstanding Performance Award” from the Commission on Cancer of the American College of Surgeons (2010), the Prostate Net’s “In the Know” National Award (2007), the UMDNJ School of Public Health “Faculty Community Service Award”(2007), and the first of the American Society of Clinical Oncology “Travel Awards” for outstanding work (1985). At NJMS, he was elected to membership in Sigma Xi chapter (1992) and as a Faculty member to the Alpha Omega Alpha [ΑΩΑ] Honor Medical Society, Beta Chapter (inducted 2003). For the latter, he has served as an officer as the Assistant Secretary/Treasurer since 2006, and helped to develop its Research Award.

Dr. Weiss’ research focuses on epidemiology, public health, study design and methodology, evaluation, policy issues and interdisciplinary studies and projects.  These have primarily been related to cancer, asthma, retroviruses including HIV/AIDS and HTLV, infectious diseases, methodological and policy issues, and bioethics.  In addition, he is the PI of several community-outreach initiatives (including the implementation and evaluation of structured tool sets for individuals to improve their health) and PI/co-PI of a series of studies concerning asthma with key new understanding of asthma epidemiology as well as policy implications.  He is the PI of a set of prospective cohort studies numbering ~10,000 injection drug users begun in the 1980’s, over 30 years ago, which is linked to personal identifying information and  a biospecimen collection of ~ 100,000 vials.  

Dr. Weiss has authored over 350 published, peer-reviewed medical articles, chapters and abstracts. Among his research accomplishments (as lead or senior author, except as noted):

  • First assessment of the prototype HIV screening test.
  • Part of the team describing the 2nd case worldwide of HTLV-II infection.
  • First demonstration of high infection rates with HTLV-II in drug users.
  • First report that among persons seropositive for HIV antibody, adverse outcomes had significant latency, and these steadily mounted over time to high rates of severe disease and death.
  • First demonstrated US case (2nd worldwide) of occupational acquisition of HIV in healthcare workers, associated this with HIV needlestick) exposure, and leading to vast changes in the workplace.
  • First case of occupational acquisition of HV in research workers.
  • First US case of HIV-2 – detected at University Hospital, Newark.
  • First demonstration of female to male sexual transmission of HIV.
  • Part of the team documenting the 2nd case of female to female HIV transmission.
  • Wrote substantial parts of the first NJ State Cancer Plan, and then led much of its statewide implementation.
  • First demonstration that the latency from initial asbestos exposure until development of mesothelioma is far longer than has been generally understood.
  • First to demonstrate that the US epicenter for HIV infection in injection drug users centered about NYC, and the first to enroll women in an HIV-era cohort study.
  • First to assess geographic distribution of asthma in children across an entire state.
  • First to discover confirmed very high rates of HCV in IDU’s, presaging the epidemic consequences of HCV (liver failure and hepatocellular carcinoma).
  • A member of the team demonstrating immunologic abnormalities associated with HTLV-II, such as spontaneous lymphocyte proliferation and lymphocyte subset changes.

Dr. Weiss is the immediate past Chair of the International Joint Policy Committee of the Societies of Epidemiology (see: www.ijpc-se.org). He has continuously served on the Executive Board of the NJPHA since 1993, through the terms of over a dozen NJPHA presidents, and the founding Chair of its Epidemiology Section. He is a past chair of the Epidemiology Section and past vice-chair of the Science Board of the American Public Health Association. He is a longstanding member of the Coordinating Committee of the Pediatric/Adult Asthma Coalition of NJ and co-chair of its Evaluation Workgroup, and the Community Liaison Physician of the NJMS/University Hospital Oncology Program to the CoC and the vice-chair of its Oncology Committee.  

As the founder and director of the Essex County Cancer Coalition and of its expanded successor, the Essex-Passaic Chronic Disease Coalition (a.k.a. the Essex-Passaic Wellness Coalition; http://web.njms.rutgers.edu/EPWC), he helps implement community-based education, outreach, screening and prevention of cancer and is a public policy advocate.   

His RBHS teaching has focused on evidence-based medicine approaches and critical analysis of medical literature, and the epidemiology and prevention of both chronic and infectious diseases.  He served in 2012-13 as the co-course director of the 2nd year NJMS “Disease Processes, Prevention & Therapeutics” course. He also teaches in the RBHS School of Public Health.  

Other professional affiliations include the NJ Allergy, Asthma & Immunology Society, the NY Allergy and Asthma Society, the American Society of Clinical Oncology, Alpha Omega Alpha (the medical honor society; he is the assistant secretary-treasurer of the Beta Chapter of NJ), the Society for Epidemiologic Research, the International Epidemiological Association, and one of the Founding Members of the Infectious Disease Society of NJ.  He is a past Fellow of the Infectious Diseases Society of America. He’s been in leadership roles for each of the four North American Congresses of Epidemiology.

Professor Stanley H. Weiss, MD, FACP, FACE
Professor of Medicine, Rutgers Biomedical and Health Sciences (RBHS) - NJ Medical School - Prof. of Epidemiology, RBHS School of Public Health